A-01 Registration at the conference venue Tuesday 14:00-18:00 |
A-02 Opening ceremony, welcome reception and dinner Tuesday 19:00-22:00 |
B-01 Registration at the conference venue Wednesday 08:00-08:45 |
B-02 Welcome and Introduction Wednesday 08:45-09:00 |
B-03 Praveen Thokala Overview and implementation of multi criteria decision analysis (MCDA) for benefit-risk assessment Wednesday 09:00-09:30 |
B-04 Andreas Kouroumalis European regulatory views on benefit-risk assessment methodologies - role of MCDA and other model-based approaches Wednesday 09:30-10:00 |
B-05 Kevin Marsh Current practices and gaps in benefit-risk assessment: opportunities for combining MCDA with model-based approaches Wednesday 10:00-10:30 |
B-06 Coffee break, poster and software session I: posters in Group I (with poster numbers starting with I-) are accompanied by their presenter Wednesday 10:30-12:00 |
B-07 Neeraj Gupta Model-Informed Drug Development (MIDD) for ixazomib, an oral proteasome inhibitor Wednesday 12:00-12:20 |
B-08 Nadia Terranova Simulation analysis of absolute lymphocytes counts (ALC) and relapse rate (RR) following cladribine (re-)treatment rules in subjects with relapsing-remitting multiple sclerosis (RRMS) Wednesday 12:20-12:40 |
B-09 Announcement of ACoP8 Wednesday 12:40-12:45 |
B-10 Lunch Wednesday 12:45-14:10 |
B-11 Joe Standing Scaling pharmacodynamics in children: Lessons from immunology, infectious diseases and critical care Wednesday 14:10-14:50 |
B-12 Nick Holford Scaling renal function in neonates and infants to describe the pharmacodynamics of antibiotic nephrotoxicity Wednesday 14:50-15:10 |
B-13 Tea break, poster and software session II: posters in Group II (with poster numbers starting with II-) are accompanied by their presenter Wednesday 15:10-16:40 |
B-14 Hanna Silber Baumann Using pharmacokinetic simulation to guide dose escalation decisions for targeted IL2v immunocytokines Wednesday 16:40-17:00 |
B-15 Simon Buatois Modelling approaches in dose finding clinical trial: Simulation-based study comparing predictive performances of model averaging and model selection. Wednesday 17:00-17:20 |
B-16 Yuri Kheifetz Model-based individual managing of thrombocytopenia during multi-cyclic chemotherapy Wednesday 17:20-17:40 |
B-17 Jurgen Langenhorst High exposure to fludarabine in conditioning prior to allogeneic hematopoietic cell transplantation predicts impaired CD4 reconstitution and lower probability of survival Wednesday 17:40-18:00 |
C-01 Elisa Borella Paediatric trial design optimization using prior knowledge in combination with modelling & simulations Thursday 08:30-08:55 |
C-02 John Diep Host-Pathogen interactions: A mechanism-based disease progression model to describe the pathogenesis of Acinetobacter baumannii pneumonia Thursday 08:55-09:20 |
C-03 Morris Muliaditan Model-based rationale for drug combinations in tuberculosis Thursday 09:20-09:45 |
C-04 Presentation of Lewis Sheiner student session awards Thursday 09:45-09:50 |
C-05 Coffee break, poster and software session III: posters in Group III (with poster numbers starting with III-) are accompanied by their presenter Thursday 09:50-11:20 |
C-06 Robert Leary An overview of non-parametric estimation methods used in population analysis Thursday 11:20-12:00 |
C-07 Mats Karlsson A comparison of performance between parametric and nonparametric estimation for nonlinear mixed-effects models Thursday 12:00-12:20 |
C-08 Announcement for WCoP 2020 Thursday 12:20-12:25 |
C-09 Lunch Thursday 12:25-13:40 |
C-11 Kristin Karlsson Regulatory pharmacometrics in the EU in practice and the role of the Modelling and Simulation Working Group Thursday 13:45-14:15 |
C-12 Anna Nordmark The new draft EMA Guidance on PBPK – The qualification of the intended use concept Thursday 14:15-14:45 |
C-13 Tea break, poster and software session IV: posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter Thursday 14:45-16:15 |
C-14 In memoriam Matt Hutmacher Thursday 16:15-16:20 |
C-15 Wojciech Krzyzanski Correction of the likelihood function as an alternative for imputing missing covariates Thursday 16:20-16:40 |
C-16 Henrik Bjugård Nyberg SADDLE_RESET: more robust parameter estimation with a check for local practical identifiability Thursday 16:40-17:00 |
C-17 Dmitry Onishchenko Joint modeling of overall survival and tumor size dynamics in non-small cell lung cancer: Clinical trial simulations and validation of predictions at study and subject levels Thursday 17:00-17:20 |
C-18 Eva Germovsek Handling frequent observations of composite scores: Application to PROs in COPD Thursday 17:20-17:40 |
C-19 Social event
|
D-01 Markus Krauß Translational systems pharmacology for acquisition of knowledge and prediction of drug pharmacokinetics across patient populations Friday 09:00-09:20 |
D-02 Robin Michelet PBPK modeling of propofol using the middle out approach Friday 09:20-09:40 |
D-03 Miro Eigenmann Therapeutic antibody concentrations at the biophase Friday 09:40-10:00 |
D-04 Alan Maloney The 6 biggest pharmacometrics modelling mistakes! Friday 10:00-10:25 |
D-05 Preview of PAGE2018 Friday 10:25-10:30 |
D-06 Coffee break Friday 10:30-11:15 |
D-07 Richard Höglund Pharmacokinetic-pharmacodynamic modelling of artesunate in patients with drug resistant and sensitive malaria Friday 11:15-11:35 |
D-08 Salvatore D'Agate Model-based screening of compounds for the treatment of Chagas disease, a neglected tropical disease. Friday 11:35-11:55 |
D-09 Carolina Llanos-Paez Balancing efficacy and reduction in renal function to optimize initial gentamicin dosing in children with cancer Friday 11:55-12:15 |
D-10 Closing remarks Friday 12:15-12:25 |
D-11 Audience input for potential PAGE2018 topics Friday 12:25-12:40 |
I-01 Martina Liebich Modelling of Dexamethasone in Paediatric Leukaemia Patients using a Population Pharmacokinetic Approach Wednesday 10:30-12:00 |
I-02 Klaus Lindauer Model Simplification Wednesday 10:30-12:00 |
I-03 Dan Liu Application of Global Sensitivity Analysis Methods to Determine the most Influential Parameters of a Minimal PBPK Model of Quinidine Wednesday 10:30-12:00 |
I-04 Rocio Lledo PK/PD modelling of an anti-FcRn mAb to optimise FIM design - translation from cyno to human Wednesday 10:30-12:00 |
I-05 Florence Loingeville Using Hamiltonian Monte-Carlo to design longitudinal count studies accounting for parameter and model uncertainties Wednesday 10:30-12:00 |
I-06 Amelia Deitchman Tigecycline-Tetracycline Combination Modeling against Pseudomonas aeruginosa: Application of the General Pharmacodynamic Interaction Term in Various Interaction Models Wednesday 10:30-12:00 |
I-07 Dominik Lott Tolerance modeling: effects of the selective S1P1 receptor modulator ponesimod on heart rate Wednesday 10:30-12:00 |
I-08 Rubin Lubomirov Population pharmacokinetic-based interspecies allometric scaling and prediction of first-in-human (FIH) pharmacokinetics of a new anticancer agent Wednesday 10:30-12:00 |
I-09 Inga Ludwig Correlative analysis of response to treatment and biomarker levels in a setting with a time-to-event efficacy outcome and sparse biomarker data Wednesday 10:30-12:00 |
I-10 John C Lukas Order in patch absorption rates? Wednesday 10:30-12:00 |
I-11 Sreenath M Krishnan Influence of the number of tumor size measurements on model-derived tumor size metrics and prediction of survival Wednesday 10:30-12:00 |
I-12 Lei Ma Dupilumab dose selection for a phase 3 study in asthma patients: pharmacokinetic/pharmacodynamic (PK/PD) modelling and clinical trial simulation Wednesday 10:30-12:00 |
I-13 Vincent Madelain Modeling viral kinetics predicts a rapid establishment of the cytotoxic immune response targeting distinct infected cell compartments in SIV controller macaques (ANRS SIC study) Wednesday 10:30-12:00 |
I-14 Paolo Magni Execution of complex Bayesian workflows with the DDMoRe Interoperability Framework: a case study in the diabetes area Wednesday 10:30-12:00 |
I-15 Corinna Maier Robust parameter estimation for dynamical systems from outlier-corrupted data Wednesday 10:30-12:00 |
I-16 Victor Mangas-Sanjuan Semi-mechanistic Pharmacodynamic model of complex receptor-hormone dynamics Wednesday 10:30-12:00 |
I-17 Ben Margetts Modelling Cytomegalovirus Growth Kinetics in Immunocompromised Children Wednesday 10:30-12:00 |
I-18 Dimitris Maris Asymptotic Analysis on a TMDD model: Control of the process Wednesday 10:30-12:00 |
I-19 Emma Martin Using mixed effects modelling improves detection of drug-gene interactions in mouse trials Wednesday 10:30-12:00 |
I-20 Paolo Mazzei Translational model-based approach to assist the dose-range selection of an antibody-drug conjugate entering Phase I Wednesday 10:30-12:00 |
I-21 Nicola Melillo Multiscale mechanistic models in Systems Pharmacology: development of a model describing Atorvastatin pharmacokinetics through integration of metabolic network in Physiologically Based Pharmacokinetic models. Wednesday 10:30-12:00 |
I-22 Sandrine Micallef Evaluation of tumor kinetics metrics as early endpoint to support decision making in early drug development Wednesday 10:30-12:00 |
I-23 Joske Millecam A new approach in pediatric drug design: the development of a pediatric pig model. Part II: The maturation of hepatic cytochrome P450 enzymes using enzyme activity and proteomics Wednesday 10:30-12:00 |
I-24 Jonathan Mochel One Health: Translational and Reverse Translational Modeling of Inflammatory Bowel Disease using an advanced Boolean Network Wednesday 10:30-12:00 |
I-25 Daniel Moj Application of a physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat to improve dosing regimens in adults Wednesday 10:30-12:00 |
I-26 Tadakatsu Nakamura Population Pharmacokinetic Analysis of Compound A and Its Metabolite in Healthy Subjects and Patients with Diabetic Nephropathy Wednesday 10:30-12:00 |
I-27 Srividya Neelakantan Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects with Severe Hemophilia A Across All Ages Wednesday 10:30-12:00 |
I-28 Asuka Suzuki A Bayesian approach for population pharmacokinetic modeling of alcohol in Japanese Subjects Wednesday 10:30-12:00 |
I-29 Thu Thuy Nguyen Population pharmacodynamic model of bronchodilator response to salbutamol in wheezy preschool children Wednesday 10:30-12:00 |
I-30 Rikard Nordgren Calling C functions from NONMEM Wednesday 10:30-12:00 |
I-31 Ana Novakovic A longitudinal model linking absolute lymphocyte count (ALC) and volume of T2 lesions to expanded disability status scale (EDSS) in patients with relapsing-remitting multiple sclerosis (RRMS) Wednesday 10:30-12:00 |
I-32 Kayode Ogungbenro Sparse sampling design for characterizing individual PK of recombinant factor VIII fusion protein (rFVIIIFc) in prophylactic treatment of Hemophilia A Wednesday 10:30-12:00 |
I-33 Boram Ohk Population Pharmacokinetics of Tacrolimus in Healhty Korean Subjects:role of CYP3A5 genotype and metabolite Wednesday 10:30-12:00 |
I-34 Olafuyi Olusola The Use of Physiologically Based Pharmacokinetic Modelling in Assessing Drug–drug Interactions Associated with Antimalarial Treatment in Paediatrics Co-infected with Tuberculosis: A Case Study with Lumefantrine and Rifampicin. Wednesday 10:30-12:00 |
I-35 Sean Oosterholt PKPD modelling of MYCN-inhibition in vitro and in vivo in a mouse model of neuroblastoma Wednesday 10:30-12:00 |
I-36 - - Investigation of Bayesian inference in predicting tissue concentrations using RStan Wednesday 10:30-12:00 |
I-37 Maria Panselina Dose-saturable model for amoxicillin used to predict probability of response in normal and obese pediatrics Wednesday 10:30-12:00 |
I-38 Sang-In Park Population pharmacokinetic analysis of evogliptin in subjects with varying degrees of renal function Wednesday 10:30-12:00 |
I-39 Zinnia Parra-Guillen Exploring the impact of study design on unperturbed tumour growth inhibition modelling Wednesday 10:30-12:00 |
I-40 Christophe Passot In-depth assessment of the influence of anti-drug antibodies on adalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritis Wednesday 10:30-12:00 |
I-41 Dimple Patel Informing modeling and clinical trial simulation using the real world data: data content, quality and availability assessment Wednesday 10:30-12:00 |
I-42 Dimitrios Patsatzis Construction and evaluation of "global" Micahelis-Menten reduced models Wednesday 10:30-12:00 |
I-43 Sophie Peigné How to handle non-linearity in absorption: a case study in oncology Wednesday 10:30-12:00 |
I-44 Nathalie Perdaems Multi-species translational PK/PD modelling in type 2 diabetes Wednesday 10:30-12:00 |
I-45 Belén Pérez Solans Modelling tumour growth and progression free survival of breast cancer patients treated with neoadjuvant therapy Wednesday 10:30-12:00 |
I-46 Jonás Samuel Pérez-Blanco Population PK and exposure-response analysis of sleep parameters for JNJ-42847922, a novel Orexin 2 receptor antagonist Wednesday 10:30-12:00 |
I-47 Carlos Perez-Ruixo Identifying lack of adherence to antipsychotic treatment using plasma concentrations measurements Wednesday 10:30-12:00 |
I-48 Chiara Piana A model-based approach to extrapolate drug-drug interactions from rats to humans Wednesday 10:30-12:00 |
I-49 Philippe Pierrillas Application of Model-Based Adaptive Optimal Design to determine a recommended dosing regimen for combination therapy in oncology Wednesday 10:30-12:00 |
I-50 Nikhil Pillai Estimating Nonlinear Dynamic Systems in Pharmacology using Chaos Synchronization Wednesday 10:30-12:00 |
I-51 Italo Poggesi A Shiny App for the Probability of Technical Success of a New Molecular Entity in the Preclinical to Clinical Translational Phase Wednesday 10:30-12:00 |
I-52 Sebastian Polak Physiologically based pharmacokinetic model (PBPK) for the halofantrine cardiac effect prediction – proof of concept study towards the system for the antimalarial drugs cardiac safety assessment. Wednesday 10:30-12:00 |
I-53 Manuel Prado-Velasco PBPK versus PK modeling of Tacrolimus drug in patients with renal transplant as knowledge engines for personalized posology software: PhysPK® development and preliminary results Wednesday 10:30-12:00 |
I-54 Tim Preijers Population pharmacokinetic analysis of perioperative factor IX dosing in hemophilia B Wednesday 10:30-12:00 |
I-55 Angelica Quartino Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3 Wednesday 10:30-12:00 |
I-56 Christian Hove Claussen PharmTeX: a LaTeX-based open-source platform for automated reporting workflow Wednesday 10:30-12:00 |
I-57 Theo Reijmers Population PK Modeling of Dapivirine released from Vaginal Rings Wednesday 10:30-12:00 |
I-58 Didier Renard Label extension for canakinumab in Adult Onset Still’s Disease (AOSD) – Extrapolation from pediatrics to adults Wednesday 10:30-12:00 |
I-59 Christer Rimmler Development of a PBPK model to predict the pharmacokinetics of cefuroxime during surgery Wednesday 10:30-12:00 |
I-60 Christelle Rodrigues Population pharmacokinetics of the sustained-release granule formulation of valproic acid in epileptic children Wednesday 10:30-12:00 |
I-61 Amin Rostami Predicting diclofenac systemic and synovial fluid concentrations after dermal application using the Multi-Phase Multi-Layer MechDermA PBPK model Wednesday 10:30-12:00 |
I-62 Hauke Ruehs Exposure-response analysis of vilaprisan describing uterine fibroid size by population PK/PD modelling Wednesday 10:30-12:00 |
I-63 Leire Ruiz Cerdá Modeling of Interferon effector pathway after viral infection Wednesday 10:30-12:00 |
I-64 Alberto Russu Dose-conversion factors for risperidone and paliperidone formulations based on steady-state PK similarity Wednesday 10:30-12:00 |
I-65 Sunae Ryu Population pharmacokinetic model of propranolol and its metabolite reflecting the first-pass effect in patients with hepatic impairment Wednesday 10:30-12:00 |
I-66 Muhammad Waqas Sadiq A model-based comparison of absorption pharmacokinetics for a selective glucocorticoid receptor modulator administered with different inhalation devices Wednesday 10:30-12:00 |
I-68 Mark Sale Application of global search methods for parameter estimation in models with poorly defined objective function surfaces Wednesday 10:30-12:00 |
I-69 Franziska Schädeli Stark Assessing the adequacy of a minimal PK sampling schedule for individual dose adjustment decisions in a proof of mechanism (PoM) study in a special population Wednesday 10:30-12:00 |
I-70 Stein Schalkwijk Placental Transfer of Darunavir and Simulation of Fetal Exposure Wednesday 10:30-12:00 |
II-01 Nina Scherer A population pharmacokinetic (PK) model of metformin regarding immediate and extended release formulations under fasted and fed conditions Wednesday 15:10-16:30 |
II-02 Emilie Schindler The minimal continuous-time Markov pharmacometric model Wednesday 15:10-16:30 |
II-03 Rik Schoemaker nlmixr: an open-source package for pharmacometric modelling in R Wednesday 15:10-16:30 |
II-04 Johannes Schropp Target-mediated drug disposition model for a bispecific antibody: development of full model and quasi-equilibrium like approximation Wednesday 15:10-16:30 |
II-05 Pascal Schulthess Frequency-domain response analysis for quantitative systems pharmacology models Wednesday 15:10-16:30 |
II-06 Bernard Sebastien Pharmacokinetic/Pharmacodynamic Modelling of Recurrent Adverse Events as Function of Drug Concentration and Time Wednesday 15:10-16:30 |
II-07 Malte Selch Larsen Using repeated-time-to-event modelling and simulation of spontaneous bleeding events in the F8 KO rat model for informed decision making of study design Wednesday 15:10-16:30 |
II-08 Marina Senek Population pharmacokinetic model for levodopa/carbidopa microtablets in Parkinson’s disease patients and healthy subjects Wednesday 15:10-16:30 |
II-09 Jennifer Sheng Joint modeling of time-varying exposure data and progression-free survival in elotuzumab-treated patients with relapsed/refractory multiple myeloma Wednesday 15:10-16:30 |
II-10 Satoshi Shoji Slow drug-target complex kinetics and first dose overestimation of free target suppression in target-mediated drug disposition (TMDD) approximation models: An evaluation for tanezumab a NGF antibody for treatment of pain Wednesday 15:10-16:30 |
II-11 Mahendra Shukla Population Pharmacokinetic-Pharmacodynamic modeling of furosemide for anti-hypertensive effect Wednesday 15:10-16:30 |
II-13 Sarah Siederer Model Based Extrapolation Approach Driving a Streamlined Clinical Development Plan for Inhaled Oxytocin Wednesday 15:10-16:30 |
II-14 Giovanni Smania The role of modelling and simulation in the paediatric investigation plan of a xanthine oxidase inhibitor for tumor lysis syndrome prevention Wednesday 15:10-16:30 |
II-15 Konstantina Soulele Population pharmacokinetic analysis of inhaled budesonide in asthma patients Wednesday 15:10-16:30 |
II-17 Sabine Stuebler Towards a systems biology model for inflammatory bowel disease Wednesday 15:10-16:30 |
II-19 Waroonrat Sukarnjanaset Performance of FOCEI vs SAEM in simple population pharmacokinetic analysis of rich, medium and sparse data. Wednesday 15:10-16:30 |
II-20 Monika Sundqvist Preclinical pharmacokinetic-pharmacodynamic modelling to guide first-time-in-human studies with the anti-miR-103/107, RG-125 (AZD4076) Wednesday 15:10-16:30 |
II-21 Ajit Suri Population Pharmacokinetic Modeling of Brentuximab Vedotin, a CD30-Directed Antibody-Drug Conjugate, and its cytotoxic payload (MMAE) in Patients With Various Hematological Malignancies Wednesday 15:10-16:30 |
II-22 Elin Svensson Linking rifampicin exposure to treatment response over 6 months in patients with pulmonary tuberculosis Wednesday 15:10-16:30 |
II-23 Lénaïg Tanneau Bedaquiline’s exposure-response relationship evaluated with data from the observational study C209 Wednesday 15:10-16:30 |
II-24 Joel Tarning Population pharmacokinetic properties of piperaquine in falciparum malaria: An individual participant data meta-analysis Wednesday 15:10-16:30 |
II-25 Adrien Tessier Investigating the PK/PD relationship of a new pro-apoptotic drug through tumor growth inhibition modelling in NUDE rats Wednesday 15:10-16:30 |
II-26 Donato Teutonico Development of a PBPK model to describe late colonic absorption after oral administration Wednesday 15:10-16:30 |
II-27 Tjokosela Tikiso Population Pharmacokinetics of Abacavir in HIV-infected African children Wednesday 15:10-16:30 |
II-28 Valentina Topic Vucenovic Nonlinear mixed effects modelling approach for investigation of 131I kinetics in patients with benign thyroid disease Wednesday 15:10-16:30 |
II-29 Elena Tosca A PK/PD model for tumor-in-host growth kinetics following administration of an antiangiogenic agent given alone or in combination regimens Wednesday 15:10-16:30 |
II-30 Mirjam Trame Translational in-vitro in-vivo model to correlate HIPS derived cardiomyocyte contractility assay and in-vivo dog telemetry based dPdtmax measurements Wednesday 15:10-16:30 |
II-31 Alexios Tsiligiannis Optimization of a paediatric FDC tablet and dosing regimen for the first line treatment of tuberculosis. Wednesday 15:10-16:30 |
II-32 Periklis Tsiros Bayesian Whole Body Population Physiologically Based Pharmacokinetic Approach for Characterization of Interindividual Variability of Diazepam Wednesday 15:10-16:30 |
II-33 Eirini Tsotsou Population pharmacokinetics of gentamycin in hospitalized ICU patients Wednesday 15:10-16:30 |
II-34 Denise Feick Physiologically-Based Pharmacokinetic (PBPK) Modeling of the CYP2C8 Substrate Pioglitazone Wednesday 15:10-16:30 |
II-35 Zofia Tylutki Simulation of pharmacokinetics of amitriptyline and nortriptyline and their common effect on human cardiac electrophysiology in healthy population Wednesday 15:10-16:30 |
II-36 Sebastian Ueckert Solving linear ODEs using Krylov subspace projection methods Wednesday 15:10-16:30 |
II-37 Sami Ullah Population pharmacokinetic analysis of intravenous telavancin in healthy subjects undergoing plasma and tissue microdialysis Wednesday 15:10-16:30 |
II-38 Moreno Ursino dfpk: an R package for a practical implementation of PK measurements in dose-finding studies Wednesday 15:10-16:30 |
II-39 Pavan Vaddady A Comprehensive Model-Based Meta-Analysis (MBMA) of Diabetes Studies in Type 2 Diabetes Mellitus Patients to Quantify the Relationship between HbA1c and Fasting Plasma Glucose Wednesday 15:10-16:30 |
II-40 Elodie Valade Population Pharmacokinetic Modeling of Simeprevir – Odalasvir Interaction in Healthy Volunteers Wednesday 15:10-16:30 |
II-41 Tamara van Donge Impact of rise in anti-drug antibodies on the pharmacokinetics of the monoclonal antibody adalimumab Wednesday 15:10-16:30 |
II-42 Michiel Van Esdonk Quantifying the growth hormone lowering effect of BIM23B065 after a GH stimulation test Wednesday 15:10-16:30 |
II-43 Eline van Maanen A systems pharmacology approach unravels the dynamics of the APP pathway and unfolds Aß oligomer modulation Wednesday 15:10-16:30 |
II-44 Erno van Schaick CHF5993 a triple combination therapy for COPD patients: population PK modelling of formoterol following pMDI inhalation Wednesday 15:10-16:30 |
II-45 Rob van Wijk A parent-metabolite pharmacokinetic model of paracetamol in zebrafish Wednesday 15:10-16:30 |
II-46 Marc Vandemeulebroecke Multi-state modeling and simulation of patient trajectories after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to inform drug development Wednesday 15:10-16:30 |
II-47 Swantje Völler Normalisation weight in a covariate function affects the relative standard error of clearance: an example with paediatric data Wednesday 15:10-16:30 |
II-48 Veronika Voronova Evaluation of immediate release exenatide effects on gastric motility and intestinal glucose absorption using a systems pharmacology model Wednesday 15:10-16:30 |
II-49 Janet Wade Population PK analysis of Sym004 and the influence of variations in base model structure on covariate model building Wednesday 15:10-16:30 |
II-50 Thanaporn Wattanakul Population pharmacokinetics and cardiovascular safety of piperaquine in African patients with uncomplicated malaria Wednesday 15:10-16:30 |
II-51 Sebastian Weber Bayesian Pharmacokinetic Extrapolation from Dense Adult to Sparse Pediatric Data Wednesday 15:10-16:30 |
II-52 Janak Wedagedera Statistical Power Analysis to Detect Drug-Drug Interaction between Lorezapam and Probenecid in Healthy and Renal-impaired Populations Using PBPK Modelling and the Simcyp R Package Wednesday 15:10-16:30 |
II-53 Gustaf Wellhagen Impact of genotype assumption in a semi-mechanistic PK model of metformin Wednesday 15:10-16:30 |
II-54 Thomas Wendl The Open Systems Pharmacology Suite (PK-Sim® & MoBi®): An open source solution for whole-body physiologically based pharmacokinetics and -dynamics Wednesday 15:10-16:30 |
II-55 Sebastian Wicha The purpose determines the predictive performance: Comparison of four population pharmacokinetic models of methotrexate. Wednesday 15:10-16:30 |
II-56 Mélanie Wilbaux Effects of Formula Milk on Weight Changes in Healthy Term and Preterm Neonates Wednesday 15:10-16:30 |
II-57 Francis Williams Ojara Examining the relationship between paclitaxel exposure and peripheral neuropathy in non-small cell lung cancer Wednesday 15:10-16:30 |
II-58 Jan-Georg Wojtyniak Physiologically-based Pharmacokinetic (PBPK) Modeling of Simvastatin Drug-Drug Interactions with Rifampin, Clarithromycin and Drug-Gene Interaction with ABCG2 Wednesday 15:10-16:30 |
II-60 Gudrun Wuerthwein Population Pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar® in children with ALL Wednesday 15:10-16:30 |
II-61 Rujia Xie Population pharmacokinetics of PF-04447943 in healthy volunteers (HV), adult patients with Alzheimer's disease (AD) and patients with Sickle Cell Disease (SCD) Wednesday 15:10-16:30 |
II-62 Joao Paulo Ximenez Population pharmacokinetic of tamoxifen and its metabolites in breast cancer patients Wednesday 15:10-16:30 |
II-63 Christine Xu Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis Wednesday 15:10-16:30 |
II-64 Dong-Seok Yim Discrepancy between in vitro potency and in vivo efficacy in human - Implications in PK-PD modeling Wednesday 15:10-16:30 |
II-65 Anyue Yin Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis Wednesday 15:10-16:30 |
II-66 Gunnar Yngman Practical considerations for using the full random effects modeling (FREM) approach to covariate modeling Wednesday 15:10-16:30 |
II-67 Zakaria Zaril A Mechanistic Pharmacokinetic Approach to the Development of Predictive Models in HIV-malaria co-infection. Wednesday 15:10-16:30 |
II-68 Chiara Zecchin Quantitative modelling to assess target engagement and pharmacology in early clinical development of an anti-OSM humanised mAb Wednesday 15:10-16:30 |
II-69 Meng Zhaoling Exposure/Response modeling for sarilumab dose regimens benefit/risk assessment Wednesday 15:10-16:30 |
II-70 Jochen Zisowsky Simulation Study on a Method for PK-QT Analyses When Several Active Compounds or Metabolites Are Present Wednesday 15:10-16:30 |
III-01 Elin Boger Drug targeting in pulmonary sub-epithelial compartments predicted through systems pharmacology modelling Thursday 09:50-11:20 |
III-02 Esther Encinas Application of modelling and simulation (M&S) methods within the context of a paediatric-use marketing authorisation (PUMA) application Thursday 09:50-11:20 |
III-03 Elvira Erhardt Comparison of pharmacokinetic parameters estimated by the experimental R package 'nlmixr' and MONOLIX Thursday 09:50-11:20 |
III-04 Ruben Faelens Clinical trial optimization of efficacy studies in slowly progressive diseases Thursday 09:50-11:20 |
III-05 Kevin Feng Study and application of nonparametric and parametric population modeling for automatic subpopulation classification to CYP2D6 phenotype compounds and pediatric age groups Thursday 09:50-11:20 |
III-06 Cecilia Fosser Model based predictions of the PTG-100 pharmacodynamic responses in ulcerative colitis patients Thursday 09:50-11:20 |
III-07 Jose Francis Influence of nevirapine and ritonavir/lopinavir based antiretroviral therapy on Lumefantrine exposure in HIV-1 infected patients. Thursday 09:50-11:20 |
III-08 Aline Fuchs Minimization of a utility function for optimizing the dosing frequency of amoxicillin administration in neonates according to a fixed PK/PD index Thursday 09:50-11:20 |
III-09 Saskia Fuhrmann Model-based comparison of mAb clearance in pediatric populations* Thursday 09:50-11:20 |
III-10 María García-Cremades Mechanistic multi-scale systems pharmacokinetics model applied for the anticancer drug gemcitabine in pancreatic cancer Thursday 09:50-11:20 |
III-11 Iain Gardner A Whole body Physiologically based Pharmacokinetic Model for Antibody drug conjugates - model development and validation in rat Thursday 09:50-11:20 |
III-13 Silke Gastine Population Pharmacokinetics of Micafungin in critically ill patients - evaluation of a fixed dose regimen Thursday 09:50-11:20 |
III-14 Francois Gaudreault Circadian quantitative system pharmacology model to inform clinical study design and translation to human Thursday 09:50-11:20 |
III-15 Parviz Ghahramani Antimicrobial Drug Development Common Practices in PK-PD Model Selection and Common Misconceptions Thursday 09:50-11:20 |
III-16 Anais Glatard Varenicline exposure is associated with abstinence from smoking in a cohort of smokers from the general population Thursday 09:50-11:20 |
III-17 Ignacio Gonzalez-Garcia Comparison of FO – FOCE population parameter estimation methods in PhysPK 2.0 against NONMEM 7.3 Thursday 09:50-11:20 |
III-18 Sungwoo Goo Population pharmacokinetics(PK)/Pharmacodynamics(PD) modeling and simulation of vancomycin in pediatric infectious patients Thursday 09:50-11:20 |
III-19 Verena Gotta Conceptual evaluation of urea rebound in pediatric hemodialysis patients by a physiology-based pharmacokinetic simulation study Thursday 09:50-11:20 |
III-20 Sebastiaan Goulooze Kernel-based visual hazard comparison (kbVHC): a simulation-free diagnostic for parametric repeated time-to-event models Thursday 09:50-11:20 |
III-21 Silvia Grandoni Evaluation of a minimal WB-PBPK platform supporting different routes of administration Thursday 09:50-11:20 |
III-22 Ana-Marija Grisic Towards understanding the loss of response to infliximab in patients with inflammatory bowel disease: A population PK modelling approach Thursday 09:50-11:20 |
III-23 Benjamin Guiastrennec Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in human Thursday 09:50-11:20 |
III-24 Monia Guidi Adequacy of open-loop Target Controlled Infusion devices during anesthesia Thursday 09:50-11:20 |
III-25 Anubha Gupta Power calculation methods to detect covariates effect when combining observed and simulated data. Thursday 09:50-11:20 |
III-26 Serge Guzy Population Pharmacokinetic of L-DOPA and its main metabolites: Use of the Phoenix based QRPEM algorithm Thursday 09:50-11:20 |
III-27 Bengt Hamrén Pharmacokinetic and exposure-response analyses supporting ticagrelor dosing recommendation in patients with prior myocardial infarction (PEGASUS-TIMI 54) Thursday 09:50-11:20 |
III-28 Nina Hanke Physiologically-based pharmacokinetic (PBPK) modeling of alfentanil as a CYP3A4 victim drug Thursday 09:50-11:20 |
III-29 Niklas Hartung Quantifying adaptive resistance in bacteria using well-designed dynamic time-kill curve experiments Thursday 09:50-11:20 |
III-30 Paul Healy Impact of metabolic polymorphism on the exposure to tramadol and its active metabolite in children Thursday 09:50-11:20 |
III-31 Lee Heechan A population parmacokinetic analysis of fimasartan, a novel angiotensin-receptor antagonist, in healthy subjects and patients with hypertension Thursday 09:50-11:20 |
III-32 Eleanor Howgate Sensitivity analysis of P-glycoprotein Ki values in dynamic DDI predictions Thursday 09:50-11:20 |
III-33 Gailing Li Mechanism-Based Modeling In Chronic Heptatis B Thursday 09:50-11:20 |
III-34 Moustafa M. A. Ibrahim Model-based diagnostics post-processing for fast automated model building; show-cased with residual error models and CWRES. Thursday 09:50-11:20 |
III-35 Ibrahim Ince Extension of a pregnancy physiologically-based pharmacokinetic model for renally cleared drugs to the postpartum period Thursday 09:50-11:20 |
III-36 Itziar Irurzun-Arana Population PD modelling of circulating biomarkers in patients with melanoma treated with interferon alpha2b Thursday 09:50-11:20 |
III-37 Masoud Jamei Virtual Bioequivalence Assessment of Two Tramadol Formulations using the Advanced Dissolution Absorption and Metabolism (ADAM) model via Simcyp R Package Thursday 09:50-11:20 |
III-38 Candice Jamois Quantification of Anti-Drug-Antibodies (ADA) Impact on Drug Exposure Using a Population PK modeling Approach Thursday 09:50-11:20 |
III-39 Julie Janssen Clinical trial simulations to optimize dose finding studies in paediatric oncology Thursday 09:50-11:20 |
III-40 Jihyun Jeon Pharmacokinetic modeling of Donepezil after transdermal administration in rat Thursday 09:50-11:20 |
III-41 Jin Jin Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3 Thursday 09:50-11:20 |
III-42 Martin Johnson Exposure response relationship for interstitial lung disease (ILD) events following osimertinib treatment Thursday 09:50-11:20 |
III-43 Koen Jolling CHF5993 a triple combination therapy for COPD patients: population pharmacokinetic modelling of beclometasone-17-monopropionate (B17MP) following pMDI inhalation. Thursday 09:50-11:20 |
III-44 Siv Jonsson Placebo and drug response assessment on Unified Parkinson’s Disease Rating Scale using longitudinal Item Response Modelling Thursday 09:50-11:20 |
III-45 Matts Kågedal Herceptin in HER2-positive Gastric Cancer: Evaluation of Exposure-Response with Two Dose Levels. Thursday 09:50-11:20 |
III-46 Vangelis Karalis On the population pharmacokinetics and the enterohepatic recirculation of inhaled formoterol in asthma patients Thursday 09:50-11:20 |
III-47 Johannes Kast Antibiotic Efficacy during Spaceflight: Impact of Simulated Microgravity on Killing of S. pneumoniae by Ciprofloxacin Thursday 09:50-11:20 |
III-48 Tatiana Khariton Human Population PK Model, Dose Selection and Target Attainment Simulations for CF-301 - a Novel Antibacterial Lysin Thursday 09:50-11:20 |
III-49 Yu Kyong Kim Population Pharmacokinetic Model Development for Long-Acting Intramuscular Injection of Drug X in Healthy Subjects Thursday 09:50-11:20 |
III-50 Yun Kim A population pharmacokinetic analysis of voriconazole according to CYP2C19 phenotype in healthy subjects Thursday 09:50-11:20 |
III-51 Lena Klopp-Schulze Exploring and explaining variability in tamoxifen and endoxifen pharmacokinetics in breast cancer patients: A pooled analysis Thursday 09:50-11:20 |
III-52 Frank Kloprogge Pharmacodynamics of vancomycin in children Thursday 09:50-11:20 |
III-53 Ben Kluender Pharmacokinetic and Exposure-Response Analyses for Extrapolation of Efficacy of Adalimumab in Adolescent Patients with Hidradenitis Suppurativa Thursday 09:50-11:20 |
III-54 Franziska Isabelle Kluwe Population pharmacokinetics of unbound voriconazole following two different routes of administration during sequence therapy Thursday 09:50-11:20 |
III-55 Jane Knöchel A novel measure of importance of state variables for model reduction: results for the blood coagulation network Thursday 09:50-11:20 |
III-56 Gilbert Koch Characterization of heart rate and sleeping patterns in pre-term neonates Thursday 09:50-11:20 |
III-57 Yuri Kosinsky Radiation and anti-PD-L1 treatment combinations: Immune cell responses and dose scheduling optimization using a joint experimental and systems modeling approach Thursday 09:50-11:20 |
III-58 Pavel Kovalenko Pharmacodynamic (PD) model of neutrophil margination to describe transient effect of sarilumab on absolute neutrophil count (ANC) in patients with rheumatoid arthritis (RA) after single-dose administration Thursday 09:50-11:20 |
III-59 Anu Shilpa Krishnatry Population pharmacokinetics and pharmacodynamics of GSK525762 in patients with solid tumors Thursday 09:50-11:20 |
III-60 Anders Kristoffersson A Novel Mechanism-Based Pharmacokinetic-Pharmacodynamic Model Describing Ceftazidime-Avibactam (CAZ-AVI) Efficacy Against β-lactamase-Producing Klebsiella pneumoniae and Pseudomonas aeruginosa Isolates Thursday 09:50-11:20 |
III-61 Fabiola La Gamba A Bayesian PK/PD model for synergy; a case study Thursday 09:50-11:20 |
III-62 Christian Laveille Population pharmacokinetics of Rimeporide: a sodium-hydrogen exchanger (NHE-1) inhibitor for patients with Duchenne Muscular Dystrophy (DMD) Thursday 09:50-11:20 |
III-63 Silvia Maria Lavezzi Modelling of rituximab clearance reduction due to ibrutinib co-administration Thursday 09:50-11:20 |
III-64 Jacob Leander Pharmacodynamic modeling of uric acid turnover and the effect of Verinurad (RDEA3170), a novel selective uric acid reabsorption inhibitor for the treatment of gout and asymptomatic hyperuricemia Thursday 09:50-11:20 |
III-65 Jong Bong Lee In silico modelling of chylomicron association to predict lymphatic absorption of small molecules Thursday 09:50-11:20 |
III-66 Donghwan Lee Population pharmacokinetic analysis of meropenem in Korean patients with acute infections Thursday 09:50-11:20 |
III-67 Jennifer Leohr A Semi-Physiologic Model of Postprandial Triglyceride Response following Anti-Obesity Therapy Thursday 09:50-11:20 |
III-68 Sarah Lezzar Population pharmacokinetics and pharmacodynamics analysis of hydroxyurea, in adult patients with sickle cell anemia (SCA), and evaluation of disease markers Thursday 09:50-11:20 |
IV-01 Khaled Abduljalil Application of Physiologically-Based Pharmacokinetic model To Predict Tramadol Concentration in human Milk Thursday 14:45-16:15 |
IV-02 João Abrantes Handling inter-occasion variability in model-based therapeutic drug monitoring Thursday 14:45-16:15 |
IV-03 Malidi Ahamadi Operating Characteristics of Stepwise Covariate Selection in Pharmacometric Modeling Thursday 14:45-16:15 |
IV-04 Pascal André Population pharmacokinetics of vancomycin delivered from active calcium sulfate bone graft substitute. Thursday 14:45-16:15 |
IV-05 Louise Andrews New population pharmacokinetic model that predicts the individual starting dose of tacrolimus following pediatric renal transplantation Thursday 14:45-16:15 |
IV-06 Usman Arshad Population pharmacokinetic model of mitotane enzyme autoinduction in adrenocortical carcinoma patients Thursday 14:45-16:15 |
IV-07 Muhammad Waqar Ashraf A semi-mechanistic model to characterize the pharmacokinetics of orally administered S-Ketamine in healthy human subjects Thursday 14:45-16:15 |
IV-08 Eduardo Asín-Prieto An Immune quantitative network aimed for viral hepatitis B Thursday 14:45-16:15 |
IV-09 Geraldine Celliere Target-mediated drug-disposition (TMDD) model comparison using the MonolixSuite Thursday 14:45-16:15 |
IV-10 Hyun-moon Back Development of a Semi-mechanistic absorption model for explaining effect of food on itraconazole Thursday 14:45-16:15 |
IV-11 Suruchi Bakshi Systems pharmacology modelling of alternative pathway of complement activation Thursday 14:45-16:15 |
IV-12 Pavel Balazki Physiologically-based Pharmacokinetics/Pharmacodynamics model of Dapagliflozin, an oral SGLT2 inhibitor Thursday 14:45-16:15 |
IV-13 Violeta Balbas-Martinez Validation of a Network Systems Pharmacology model for Inflammatory Bowel Thursday 14:45-16:15 |
IV-14 Guillaume Baneyx Population pharmacokinetic modeling of pazopanib in healthy volunteers and patients with advanced renal cell carcinoma. Thursday 14:45-16:15 |
IV-15 Catalina Barceló Modelling body mass index trajectory in HIV-infected individuals Thursday 14:45-16:15 |
IV-16 Carla Bastida Fernández Population pharmacokinetic model for intravenous tocilizumab in rheumatoid arthritis Thursday 14:45-16:15 |
IV-17 Brendan Bender A Mechanism-Based Model of Tumor Quiescence and Resistance in HER2-Negative Metastatic Breast Cancer in Patients Receiving Docetaxel or Paclitaxel Thursday 14:45-16:15 |
IV-18 Sophie Berends A Target-Mediated Drug Disposition model for infliximab in patients with Ulcerative Colitis Thursday 14:45-16:15 |
IV-19 Aliénor Bergès Dose-exposure-response model between an ATR inhibitor and peripheral monocytes Thursday 14:45-16:15 |
IV-20 Julie Bertrand Joint pharmacogenetic model of tenofovir and emtricitabine and their active intracellular metabolites in HIV Patients Thursday 14:45-16:15 |
IV-21 Souvik Bhattacharya Longitudinal Parkinson’s Disease Progression Model using Item-Response-Theory Utilized to Predict Treatment Effect of Levodopa Thursday 14:45-16:15 |
IV-22 Bruno Bieth Use of population PK/PD modeling to support the regulatory approval of canakinumab as first biologic treatment in patients with periodic fever syndromes Thursday 14:45-16:15 |
IV-23 Roberto Bizzotto A model of insulin kinetics describing tests with various insulin secretion and infusion patterns by means of a consistent mechanism Thursday 14:45-16:15 |
IV-24 Agnieszka Borsuk-De Moor Tigecycline population pharmacokinetics in patients with severe sepsis or septic shock resulting from abdominal surgery Thursday 14:45-16:15 |
IV-25 Thomas Bouillon Efficient identification of the optimal dosing regimen with a nonparametric method Thursday 14:45-16:15 |
IV-26 Ari Brekkan Viggosson Parameter Estimation in Bivariate Mixed Hidden Markov Models Thursday 14:45-16:15 |
IV-27 Jantine Brussee Distinguishing between first-pass and systemic CYP3A-mediated metabolism of midazolam in preterm neonates using physiologically-based pharmacokinetic modelling Thursday 14:45-16:15 |
IV-28 Núria Buil Bruna Predicting myelosuppression from phase I data: Which model should we use? Thursday 14:45-16:15 |
IV-29 Charles Burdet Joint modeling of moxifloxacin pharmacokinetics and fecal microbiota disruption in healthy volunteers Thursday 14:45-16:15 |
IV-30 Unai Caballero Pharmacokinetic/pharmacodynamic modeling of anidulafungin time-kill curves against Candida considering antifungal resistance Thursday 14:45-16:15 |
IV-31 Sophie Callies Increase in glucose as pharmacodynamic biomarker following administration of the PI3K/mTOR inhibitor LY3023414: quantitative description using modelling. Thursday 14:45-16:15 |
IV-32 Elisa Calvier Accuracy of plasma clearance scaling from adults to children using pathway-specific covariate models: a systematic investigation using a physiologically-based pharmacokinetic workflow Thursday 14:45-16:15 |
IV-33 Letizia Carrara Which data are necessary to build a WB-PBPK model that accurately predicts exposure in the lung? A case study using Ethambutol for tuberculosis treatment Thursday 14:45-16:15 |
IV-34 Massimo Cella CHF5993 a triple combination therapy for COPD patients: population PK modelling of glycopyrronium bromide (GB) following pMDI inhalation. Thursday 14:45-16:15 |
IV-35 Marc Cerou Development and performance of npde for the evaluation of time-to-event model Thursday 14:45-16:15 |
IV-36 Anne Chain An Extrapolation Approach to Aprepitant Pediatric Drug Development Thursday 14:45-16:15 |
IV-37 Kaelig Chatel Tobramycin dose individualization using the MonolixSuite Thursday 14:45-16:15 |
IV-38 Jonathan Chauvin Longitudinal Model-Based Meta-Analysis (MBMA) for rheumatoid arthritis with Monolix Thursday 14:45-16:15 |
IV-39 Chao Chen A clinical trial simulation study to investigate and compare efficacy and toxicity findings in parallel and titration designs Thursday 14:45-16:15 |
IV-40 Dina Chernikova Inhibition of bile acids synthesis via fibroblast growth factor 19 (FGF19) through intestinal signaling: A population analysis Thursday 14:45-16:15 |
IV-41 Manoranjenni Chetty Prediction of the pharmacokinetics of renally excreted antiretrovirals in older patients, using physiologically based pharmacokinetic (PBPK) modelling. Thursday 14:45-16:15 |
IV-42 S. Y. Amy Cheung Optimising Phase 1 oncology dosing schedule of an ATR inhibitor in real time using a model informed approach to predict myelosuppression Thursday 14:45-16:15 |
IV-43 Maxwell Chirehwa A semi-physiological model for moxifloxacin pharmacokinetics which includes the effect of co-administered drugs and genetic polymorphisms Thursday 14:45-16:15 |
IV-44 Joannellyn Chiu Pre-clinical Population PK Model of CF-301 - a Novel Antibacterial Lysin Thursday 14:45-16:15 |
IV-45 Palang Chotsiri Population pharmacokinetic and time-to-event modelling of the antimalarial drug lumefantrine in young children with severe acute malnutrition Thursday 14:45-16:15 |
IV-46 Shafi Chowdhury Using “Big” NONMEM Dataset Generated from Standard SDTM to Review Data and Accelerate Model Building Process Thursday 14:45-16:15 |
IV-47 Pieter Colin Dexmedetomidine pharmacodynamics in healthy volunteers: Striking a balance between the hypnotic and sedative properties and the haemodynamic side effects. Thursday 14:45-16:15 |
IV-48 Camille Couffignal Population pharmacokinetic modelling of sustained-release lithium in the serum, erythrocytes and urine of patients with bipolar disorder. Thursday 14:45-16:15 |
IV-49 Sinziana Cristea The impact of renal transporters on paediatric renal clearance Thursday 14:45-16:15 |
IV-50 Vincent Croixmarie DDMoRe private repository linked with an in-house PK database Thursday 14:45-16:15 |
IV-51 André Dallmann Physiologically-based pharmacokinetic modeling of drugs metabolized via several CYP enzymes in populations of pregnant women Thursday 14:45-16:15 |
IV-52 Olivier David CNP520 Phase III dose selection support: Identifying the doses producing a desired reduction in CSF Aß-40 Thursday 14:45-16:15 |
IV-53 Miné De Kock Population Pharmacokinetics of Sulfadoxine and Pyrimethamine: A pooled analysis to Inform Optimal Dosing in African Children with Uncomplicated Malaria. Thursday 14:45-16:15 |
IV-54 Mailys De Sousa Mendes Predicting human foetal exposure using physiologically based pharmacokinetic models Thursday 14:45-16:15 |
IV-55 Aurelia de Vries Schultink Modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens. Thursday 14:45-16:15 |
IV-56 Neel Deferm Modeling of telmisartan disposition in sandwich-cultured rat hepatocytes. Does cryopreservation change disposition kinetics? Thursday 14:45-16:15 |
IV-57 Douglas J. Eleveld How many bits of information did my study provide? Examining Kullback-Leibler divergence, standard errors and shrinkage Thursday 14:45-16:15 |
IV-58 Chenhui Deng Tofacitinib exposure-response modeling of partial Mayo score in ulcerative colitis patients in phase 3 induction studies Thursday 14:45-16:15 |
IV-59 Menshykau Denis Computational Modelling of Personalized Hemodynamic Response to Valve Replacement Surgery in Heart Failure Patients Thursday 14:45-16:15 |
IV-60 Paolo Denti Lopinavir/Ritonavir Super-boosting Overcomes Interactions In Children Treated With Rifampicin: A Model-Based Approach For Non-Inferiority Trials Thursday 14:45-16:15 |
IV-61 Solène Desmée Mechanistic joint modelling for longitudinal PSA and survival data in advanced metastatic prostate cancer Thursday 14:45-16:15 |
IV-62 Cheikh Diack A model-based meta-marker to characterize the response to ranibizumab in wet AMD patients Thursday 14:45-16:15 |
IV-63 Christian Diedrich Towards population physiology based pharmacokinetics modelling (popPBPK) in an industrial environment Thursday 14:45-16:15 |
IV-64 Richard Dimelow Effect of dataset characteristics on estimation method performance: a TMDD model example Thursday 14:45-16:15 |
IV-65 Christiane Dings Mathematical modeling of glucose, insulin and c-peptide during the OGTT in pre-diabetic subjects: A DIRECT study Thursday 14:45-16:15 |
IV-66 Mike Dunlavey Use of distributed delay in PML Thursday 14:45-16:15 |
IV-67 Sulav Duwal Multiscale, mechanistic pipeline to assess the prophylactic efficacy of anti- HIV compounds Thursday 14:45-16:15 |
IV-68 Lisa Ehmann Is a pooled population pharmacokinetic model predictive of plasma and microdialysate pharmacokinetics of linezolid in obese and non-obese patients? Thursday 14:45-16:15 |
S-01 Robert Bauer DDEXPAND interface for coding delay differential equations based models in NONMEM During entire meeting |
S-02 Svetlana Freiberga PsN and Xpose During entire meeting |
S-03 Roger Jelliffe The Pmetrics Population Modeling and Monte Carlo Simulation, and BestDose Clinical, Software During entire meeting |
S-04 Daniel Röshammar Simulo – a platform for advanced model based simulations using R During entire meeting |
S-05 Tarjinder Sahota NMproject: Tidy, Reproducible, Script Based NONMEM projects in RStudio. A Step Toward Pharmacometric Industrialisation. During entire meeting |